A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

15402D798EC00001-EVOLVEOpenA Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)D798EC00001NCT06129864IndustrialAdultTreatmentIIIGlobalLip, Oral Cavity and PharynxMerkhofer, CristinaMedStar Health and GUMC; Medstar Washington Hospital Center : Leila SounnaThoracic/CNS/H&N/ThyroidOncology GroupMHRI Washington Cancer Institute13705Leila SounnaLeila SounnaLeila.Sounna@Medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>